Literature DB >> 33792744

[Atypical arthritis of the hands : Collagenosis-part 2].

Matthias Bollow1,2.   

Abstract

BACKGROUND: Progressive systemic scleroderma (PSS) and mixed connective tissue disease (MCTD) represent vasculitic autoimmune diseases from the group of collagenoses with manifestations in various organ systems such as the skin, the internal organs and the joints.
OBJECTIVE: To present the atypical arthritis patterns of the hands in PSS and MCTD that differ from those in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in the context of clinical and serologic findings and in consideration of the classification of PSS and MCTD.
MATERIALS AND METHODS: Narrative review based on the current literature on the subject from the radiological and rheumatological point of view.
RESULTS: In PSS, combinations of acral soft tissue atrophy, nonreactive acro-osteolysis, and interstitial calcifications can be visualized by projection radiography, which in the final stage can lead to a scleroderma claw hand. Digital pharmacoangiography of the hands can be used to reliably diagnose manifest vascular occlusions of the digital arteries. MCTD is characterized by various overlapping symptoms of at least two systemic autoimmune diseases and most frequently presents in the hand with symmetrical involvement of the PIP (proximal interphalangeal), MCP (metacarpophalangeal) and wrist joints with the manifestation of so-called "puffy fingers".
CONCLUSIONS: The presented morphological atypical arthritis patterns of the hands in PSS and MCTD differ considerably from the typical patterns in the hands in RA and PsA. MRI is useful to diagnose early stages and pharmacoangiography can be used to differentiate between temporary and manifest digital vascular occlusions.

Entities:  

Keywords:  Acro-osteolysis; Claw hands; Mixed connective tissue disease; Progressive systemic sclerosis; Puffy fingers

Mesh:

Year:  2021        PMID: 33792744     DOI: 10.1007/s00117-021-00842-2

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  48 in total

Review 1.  Criteria for the classification of early systemic sclerosis.

Authors:  E C LeRoy; T A Medsger
Journal:  J Rheumatol       Date:  2001-07       Impact factor: 4.666

Review 2.  Sentinel signs and symptoms of systemic sclerosis.

Authors:  E C LeRoy
Journal:  Curr Opin Rheumatol       Date:  1990-12       Impact factor: 5.006

Review 3.  Localized scleroderma.

Authors:  R K Schachter
Journal:  Curr Opin Rheumatol       Date:  1990-12       Impact factor: 5.006

4.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

Review 5.  Scleroderma.

Authors:  Armando Gabrielli; Enrico V Avvedimento; Thomas Krieg
Journal:  N Engl J Med       Date:  2009-05-07       Impact factor: 91.245

Review 6.  The eosinophilia-myalgia syndrome--guidelines for patient care.

Authors:  P A Hertzman; L D Kaufman; L A Love; P J Mease; R M Philen; T Pincus; N L Rosenberg; R Silver; J Varga; D J Clauw
Journal:  J Rheumatol       Date:  1995-01       Impact factor: 4.666

Review 7.  Scleroderma-like disorders.

Authors:  S Jablonska; M Blaszczyk
Journal:  Semin Cutan Med Surg       Date:  1998-03

Review 8.  [Eosinophilic fasciitis (Shulman's disease): Diagnostic and therapeutic review].

Authors:  D Sène
Journal:  Rev Med Interne       Date:  2015-09-16       Impact factor: 0.728

Review 9.  The role of nail-videocapillaroscopy in early diagnosis of scleroderma.

Authors:  Daniela Rossi; Alessandra Russo; Erika Manna; Giovanni Binello; Simone Baldovino; Savino Sciascia; Dario Roccatello
Journal:  Autoimmun Rev       Date:  2012-12-04       Impact factor: 9.754

10.  12-year followup study of epidemic Spanish toxic oil syndrome.

Authors:  L D Kaufman; M Izquierdo Martinez; J M Serrano; J J Gomez-Reino
Journal:  J Rheumatol       Date:  1995-02       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.